Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies
Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies have?
Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies has 151 citations in the OpenAlex counts ScholarIQ stores.
When was Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies published?
Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies has 2011 year in the ScholarIQ index.
What is the open-access status of Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies?
Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies has closed oa status in the ScholarIQ index.
What is the DOI of Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies?
The DOI for Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies is on the source record.
What is the PMID of Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies?
The PMID for Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies is on the source record.
What is the OpenAlex record for Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies?
The OpenAlex for Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies is on the source record.